Chemistry:SXC-2023

From HandWiki

SXC-2023 is a cystine–glutamate antiporter (SLC7A11; System xc- or Sxc) activator or glutamate modulator which is under development for the treatment of impulse control disorders such as trichotillomania (hair-pulling disorder).[1][2][3][4][5] It is also being studied for treatment of cocaine-related disorders and smoking withdrawal.[1][2] The drug is taken orally.[6] The effects of SXC-2023 in animals have been studied.[3] SXC-2023 was first described in the scientific literature by 2018.[3] It was originated by Marquette University and the University of Wisconsin at Milwaukee and is under development by Promentis Pharmaceuticals and the National Institute on Drug Abuse (NIDA).[1][2] As of June 2025, the drug is in phase 2 clinical trials.[1][2]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "SXC 2023". 2 June 2025. https://adisinsight.springer.com/drugs/800050452. 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on SXC-2023 with Synapse". 8 May 2025. https://synapse.patsnap.com/drug/f23045c896ea40f08e01e1e3e5ef6615. 
  3. ↑ 3.0 3.1 3.2 "SXC-2023: Characterization of a Novel Activator of the Cystine-Glutamate Antiporter and Potential Therapeutic for CNS Disorders". Neuropsychopharmacology. ACNP 57th Annual Meeting: Poster Session III: W72. 43 (S1): 383–527. 2018. doi:10.1038/s41386-018-0268-5. ISSN 0893-133X. https://www.nature.com/articles/s41386-018-0268-5. Retrieved 26 January 2026. 
  4. ↑ "SXC-2023: a small-molecule activator of the cystine–glutamate antiporter and potential therapeutic for central nervous system disorders is safe and welltolerated in phase I studies". Innovations in Clinical Neuroscience. CNS Summit: Selected Abstracts from the 2019 Meeting 16 (9–10): S5–S19. September 2019. PMID 33282525. 
  5. ↑ "Pharmacotherapy for trichotillomania". The Cochrane Database of Systematic Reviews 2021 (9). September 2021. doi:10.1002/14651858.CD007662.pub3. PMID 34582562. 
  6. ↑ "Promentis starts dosing in trial of SXC-2023 for trichotillomania". 18 January 2019. https://www.clinicaltrialsarena.com/news/promentis-starts-dosing/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:SXC-2023&oldid=4245865"